CN114544796A - 一种液相质谱联用测定血浆中司替戊醇的方法 - Google Patents
一种液相质谱联用测定血浆中司替戊醇的方法 Download PDFInfo
- Publication number
- CN114544796A CN114544796A CN202111535103.4A CN202111535103A CN114544796A CN 114544796 A CN114544796 A CN 114544796A CN 202111535103 A CN202111535103 A CN 202111535103A CN 114544796 A CN114544796 A CN 114544796A
- Authority
- CN
- China
- Prior art keywords
- stiripentol
- sample
- plasma
- standard
- concentration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- IBLNKMRFIPWSOY-FNORWQNLSA-N stiripentol Chemical compound CC(C)(C)C(O)\C=C\C1=CC=C2OCOC2=C1 IBLNKMRFIPWSOY-FNORWQNLSA-N 0.000 title claims abstract description 78
- 229960001897 stiripentol Drugs 0.000 title claims abstract description 78
- 238000000034 method Methods 0.000 title claims abstract description 37
- 238000004949 mass spectrometry Methods 0.000 title claims abstract description 6
- 239000007791 liquid phase Substances 0.000 title description 2
- IBLNKMRFIPWSOY-QPYRMXHWSA-N (e)-1-(1,3-benzodioxol-5-yl)-5,5,5-trideuterio-4,4-bis(trideuteriomethyl)pent-1-en-3-ol Chemical compound [2H]C([2H])([2H])C(C([2H])([2H])[2H])(C([2H])([2H])[2H])C(O)\C=C\C1=CC=C2OCOC2=C1 IBLNKMRFIPWSOY-QPYRMXHWSA-N 0.000 claims abstract description 38
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 claims abstract description 11
- 239000006228 supernatant Substances 0.000 claims abstract description 9
- 239000007788 liquid Substances 0.000 claims abstract description 5
- 239000000523 sample Substances 0.000 claims description 90
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 39
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 30
- 239000012224 working solution Substances 0.000 claims description 30
- 238000002156 mixing Methods 0.000 claims description 27
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 21
- 239000013062 quality control Sample Substances 0.000 claims description 11
- 238000003908 quality control method Methods 0.000 claims description 11
- 239000007864 aqueous solution Substances 0.000 claims description 10
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 claims description 10
- -1 polypropylene Polymers 0.000 claims description 10
- 239000004743 Polypropylene Substances 0.000 claims description 9
- 230000014759 maintenance of location Effects 0.000 claims description 9
- 229920001155 polypropylene Polymers 0.000 claims description 9
- 238000007789 sealing Methods 0.000 claims description 9
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 claims description 8
- 238000004458 analytical method Methods 0.000 claims description 7
- 238000001514 detection method Methods 0.000 claims description 7
- 239000011259 mixed solution Substances 0.000 claims description 7
- 239000000243 solution Substances 0.000 claims description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 claims description 5
- 235000019253 formic acid Nutrition 0.000 claims description 5
- 239000012496 blank sample Substances 0.000 claims description 4
- 238000004128 high performance liquid chromatography Methods 0.000 claims description 4
- 238000000589 high-performance liquid chromatography-mass spectrometry Methods 0.000 claims description 4
- 238000002347 injection Methods 0.000 claims description 4
- 239000007924 injection Substances 0.000 claims description 4
- 238000005259 measurement Methods 0.000 claims description 4
- 230000005540 biological transmission Effects 0.000 claims description 3
- 238000006243 chemical reaction Methods 0.000 claims description 3
- 238000010829 isocratic elution Methods 0.000 claims description 3
- 238000004811 liquid chromatography Methods 0.000 claims description 3
- 238000002552 multiple reaction monitoring Methods 0.000 claims description 3
- 238000004445 quantitative analysis Methods 0.000 claims description 3
- 238000005406 washing Methods 0.000 claims description 3
- 239000003146 anticoagulant agent Substances 0.000 claims description 2
- 229940127219 anticoagulant drug Drugs 0.000 claims description 2
- 238000003556 assay Methods 0.000 claims description 2
- 238000000265 homogenisation Methods 0.000 claims description 2
- 238000010813 internal standard method Methods 0.000 claims description 2
- 238000012360 testing method Methods 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 abstract description 2
- 230000006920 protein precipitation Effects 0.000 abstract description 2
- 239000012530 fluid Substances 0.000 abstract 2
- 239000012716 precipitator Substances 0.000 abstract 1
- 210000002381 plasma Anatomy 0.000 description 49
- 238000002360 preparation method Methods 0.000 description 12
- 239000012491 analyte Substances 0.000 description 7
- 238000010790 dilution Methods 0.000 description 7
- 239000012895 dilution Substances 0.000 description 7
- 238000010257 thawing Methods 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 230000008014 freezing Effects 0.000 description 6
- 238000007710 freezing Methods 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 239000011550 stock solution Substances 0.000 description 6
- 229940079593 drug Drugs 0.000 description 5
- 239000011159 matrix material Substances 0.000 description 5
- 238000011084 recovery Methods 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 238000010828 elution Methods 0.000 description 4
- 239000012071 phase Substances 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 238000012937 correction Methods 0.000 description 3
- 238000007865 diluting Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 238000013112 stability test Methods 0.000 description 3
- 210000002700 urine Anatomy 0.000 description 3
- 238000004364 calculation method Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 238000001819 mass spectrum Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- IBLNKMRFIPWSOY-UHFFFAOYSA-N 1-(1,3-benzodioxol-5-yl)-4,4-dimethyl-1-penten-3-ol Chemical compound CC(C)(C)C(O)C=CC1=CC=C2OCOC2=C1 IBLNKMRFIPWSOY-UHFFFAOYSA-N 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 102000008144 Cytochrome P-450 CYP1A2 Human genes 0.000 description 1
- 108010074922 Cytochrome P-450 CYP1A2 Proteins 0.000 description 1
- 108010026925 Cytochrome P-450 CYP2C19 Proteins 0.000 description 1
- 208000003311 Cytochrome P-450 Enzyme Inhibitors Diseases 0.000 description 1
- 102100029363 Cytochrome P450 2C19 Human genes 0.000 description 1
- 229940122280 Cytochrome P450 inhibitor Drugs 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 108010044467 Isoenzymes Proteins 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000017858 demethylation Effects 0.000 description 1
- 238000010520 demethylation reaction Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 230000023611 glucuronidation Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 239000012898 sample dilution Substances 0.000 description 1
- 238000005464 sample preparation method Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/04—Preparation or injection of sample to be analysed
- G01N30/06—Preparation
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/62—Detectors specially adapted therefor
- G01N30/72—Mass spectrometers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/86—Signal analysis
- G01N30/8624—Detection of slopes or peaks; baseline correction
- G01N30/8631—Peaks
- G01N30/8634—Peak quality criteria
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/04—Preparation or injection of sample to be analysed
- G01N2030/042—Standards
- G01N2030/045—Standards internal
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Physics & Mathematics (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Engineering & Computer Science (AREA)
- Quality & Reliability (AREA)
- Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Description
Claims (6)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111535103.4A CN114544796B (zh) | 2021-12-15 | 2021-12-15 | 一种液相质谱联用测定血浆中司替戊醇的方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111535103.4A CN114544796B (zh) | 2021-12-15 | 2021-12-15 | 一种液相质谱联用测定血浆中司替戊醇的方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN114544796A true CN114544796A (zh) | 2022-05-27 |
CN114544796B CN114544796B (zh) | 2023-09-08 |
Family
ID=81670253
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202111535103.4A Active CN114544796B (zh) | 2021-12-15 | 2021-12-15 | 一种液相质谱联用测定血浆中司替戊醇的方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114544796B (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116930368A (zh) * | 2023-07-27 | 2023-10-24 | 石家庄四药有限公司 | 一种司替戊醇异构体的检测方法 |
-
2021
- 2021-12-15 CN CN202111535103.4A patent/CN114544796B/zh active Active
Non-Patent Citations (3)
Title |
---|
NAVEEN KR DUBEY ET AL: "Enantiomeric separation and estimation of stiripentol by liquid chromatography mass spectrometer in human plasma" * |
NICOLE A. HAWKINS ET AL.: "Screening of conventional anticonvulsants in a genetic mouse model of epilepsy" * |
RYOHEI TAKAHASHI ET AL.: "Determination of Stiripentol in Plasma by High-performance Liquid Chromatography with Fluorescence Detection" * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116930368A (zh) * | 2023-07-27 | 2023-10-24 | 石家庄四药有限公司 | 一种司替戊醇异构体的检测方法 |
CN116930368B (zh) * | 2023-07-27 | 2024-03-29 | 石家庄四药有限公司 | 一种司替戊醇异构体的检测方法 |
Also Published As
Publication number | Publication date |
---|---|
CN114544796B (zh) | 2023-09-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN111366671B (zh) | 同时检测血清中18种类固醇激素的化学衍生-超高效液相色谱-串联质谱法 | |
EP2215447B1 (en) | Methods for detecting dihydroxyvitamin d metabolites by mass spectrometry | |
CN111175394B (zh) | 一种液相色谱串联质谱检测血浆儿茶酚胺及其代谢物的方法 | |
Zhang et al. | A tandem mass spectrometry assay for the simultaneous determination of acetaminophen, caffeine, phenytoin, ranitidine, and theophylline in small volume pediatric plasma specimens | |
Zoppi et al. | Performance evaluation of the new AMS system at Accium BioSciences | |
Ni et al. | Simultaneous analysis of olanzapine, fluoxetine, and norfluoxetine in human plasma using liquid chromatography-mass spectrometry and its application to a pharmacokinetic study | |
Yang et al. | High-throughput measurement of 25-hydroxyvitamin D by LC–MS/MS with separation of the C3-epimer interference for pediatric populations | |
CN114544796A (zh) | 一种液相质谱联用测定血浆中司替戊醇的方法 | |
He et al. | Determination of the sulfate and glucuronide conjugates of levornidazole in human plasma and urine, and levornidazole and its five metabolites in human feces by high performance liquid chromatography–tandem mass spectrometry | |
Xie et al. | Simultaneous quantification and pharmacokinetic investigation of selexipag and its main metabolite ACT-333679 in rat plasma by UPLC-MS/MS method | |
CN115420812B (zh) | 一种检测尿液中Calcitroic acid的方法及其应用 | |
CN111103383A (zh) | 一种液质联用同时测定人血浆中内源性皮质醇、皮质酯酮、雄烯二酮、睾酮浓度的方法 | |
CN114397379A (zh) | 一种液质联用测定血浆中奥硝唑浓度的方法 | |
CN114384170A (zh) | 一种液质联用测定血浆中氨氯地平浓度的方法 | |
CN110726799A (zh) | 同时检测血液中25羟基-维生素d3和25羟基-维生素d2含量的方法 | |
Wu et al. | A sensitive and rapid liquid chromatography-tandem mass spectrometry method for the quantification of the novel neurokinin-1 receptor antagonist aprepitant in rhesus macaque plasma, and cerebral spinal fluid, and human plasma with application in translational NeuroAIDs research | |
Xu et al. | Establishment and validation of a UPLC-MS/MS bioassay for the quantification of infigratinib in rat plasma | |
CN114384171A (zh) | 一种液质联用测定血浆中拉考沙胺浓度的方法 | |
CN112198244A (zh) | 测定血浆中阿比特龙浓度的方法 | |
CN114397380A (zh) | 一种液质联用测定血浆中西格列汀浓度的方法 | |
CN112485340A (zh) | 一种超高效液相色谱串联质谱检测血浆中1,5-脱水山梨醇的方法 | |
Magiera et al. | A rapid method for determination of 22 selected drugs in human urine by UHPLC/MS/MS for clinical application | |
CN114487185B (zh) | 一种胆固醇通路的分离鉴定方法 | |
CN114740120B (zh) | 同时定量测定阿比特龙及其五种代谢物的方法及应用 | |
CN115078621B (zh) | 一种测定血浆中依喜替康衍生物Dxd浓度的方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CP03 | Change of name, title or address |
Address after: 230000 Anhui Wanbang Pharmaceutical Building 1, Southwest Corner of Mingzhu Avenue and Huolongdi Road Intersection, High tech Zone, Hefei City, Anhui Province Patentee after: Anhui Wanbang Pharmaceutical Technology Co.,Ltd. Country or region after: Zhong Guo Address before: 230000 building A15, Liheng industrial Plaza Phase 2, intersection of Chuangxin Avenue and prosperous Avenue, high tech Zone, Hefei City, Anhui Province Patentee before: Anhui Wanbang Pharmaceutical Technology Co.,Ltd. Country or region before: Zhong Guo |
|
CP03 | Change of name, title or address |